71.99
price up icon6.83%   4.60
after-market Dopo l'orario di chiusura: 72.00 0.01 +0.01%
loading
Precedente Chiudi:
$67.39
Aprire:
$67.83
Volume 24 ore:
5.09M
Relative Volume:
6.20
Capitalizzazione di mercato:
$2.30B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-24.02
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
+46.59%
1M Prestazione:
+60.01%
6M Prestazione:
+46.53%
1 anno Prestazione:
+68.20%
Intervallo 1D:
Value
$66.90
$73.97
Intervallo di 1 settimana:
Value
$48.22
$73.97
Portata 52W:
Value
$36.61
$73.97

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name
Nome
Soleno Therapeutics Inc
Name
Telefono
650-213-8444
Name
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
SLNO's Discussions on Twitter

Confronta SLNO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLNO
Soleno Therapeutics Inc
71.99 2.30B 0 -38.99M -24.94M -2.9966
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-05 Ripresa Stifel Buy
2024-12-02 Reiterato Robert W. Baird Outperform
2024-12-02 Reiterato Stifel Buy
2024-09-03 Iniziato H.C. Wainwright Buy
2024-05-10 Iniziato Robert W. Baird Outperform
2024-02-05 Iniziato Piper Sandler Overweight
2024-01-23 Iniziato Stifel Buy
2023-11-21 Ripresa Guggenheim Buy
2020-09-29 Iniziato Guggenheim Buy
2020-01-10 Iniziato Craig Hallum Buy
2019-12-23 Iniziato Oppenheimer Outperform
2018-02-13 Reiterato Maxim Group Buy
Mostra tutto

Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie

pulisher
Mar 30, 2025

Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider

Mar 30, 2025
pulisher
Mar 29, 2025

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

10 Stocks Outperform Broader Market Last Week - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Guggenheim raises Soleno Therapeutics stock target to $81 By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Stifel raises Soleno stock target to $108 after FDA approval By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire

Mar 28, 2025
pulisher
Mar 28, 2025

Stifel raises Soleno stock target to $108 after FDA approval - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey

Mar 28, 2025
pulisher
Mar 28, 2025

Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline

Mar 28, 2025
pulisher
Mar 27, 2025

Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead

Mar 27, 2025
pulisher
Mar 27, 2025

Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily

Mar 27, 2025
pulisher
Mar 27, 2025

First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld Online

Mar 27, 2025
pulisher
Mar 27, 2025

Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Shares Are Up Today: What's Going On? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive

Mar 27, 2025
pulisher
Mar 27, 2025

Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow - Citeline News & Insights

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno stock skyrockets on FDA drug approval - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - FiercePharma

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drugSan Francisco Business Times - The Business Journals

Mar 27, 2025
pulisher
Mar 27, 2025

Piper Sandler maintains $93 target on Soleno Therapeutics stock By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Skyrockets 40% on FDA Nod for VYKAT XR - Wall Street Pit

Mar 27, 2025
pulisher
Mar 27, 2025

Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Soleno Therapeutics buy rating post FDA nod By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

SLNO stock touches 52-week high at $66.16 amid robust growth - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Soleno Therapeutics buy rating post FDA nod - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Piper Sandler maintains $93 target on Soleno Therapeutics stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Sector Update: Health Care - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Oppenheimer lifts Soleno Therapeutics stock target to $105 - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome - PMLiVE

Mar 27, 2025
pulisher
Mar 27, 2025

Why Is Soleno Therapeutics Soaring On Thursday?Soleno Therapeutics (NASDAQ:SLNO) - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno stock price target raised to $102 by Baird - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Soleno Therapeutics buy rating, $74 target - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno gains as US FDA approves its drug to treat rare genetic disorder - TradingView

Mar 27, 2025

Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Capitalizzazione:     |  Volume (24 ore):